# Booster Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/booster-therapeutics

- Industry: Biotechnology
- Headquarters: Berlin, Germany
- Website: www.boostertx.com
- Total disclosed funding: $15M
- Latest round: Seed (Jul 28, 2021)
- Investors on record: 2

## About

Based in Berlin, Germany, and founded in 2020 by Dr. Diogo R. Feleciano, and Dr. Darci J. Trader, Booster Therapeutics GmbH operates as the manufacturer of medications that activate enzymes to treat a number of difficult disorders. In October 2024, Booster Therapeutics GmbH raised USD 15 million in venture funding co-led by Apollo Health Ventures and Novo Holdings.

Booster Therapeutics is working on medicines that help activate the cell's natural way of cleaning up damaged proteins to treat various complex diseases related to proteasome problems. Proteasomes are crucial for breaking down damaged or unneeded proteins, but the function can weaken with age and illness, causing cell issues. Instead of just targeting specific proteins for removal, the firm's method aims to improve the overall activity of proteasome, helping it better recognize and eliminate misfolded proteins. Furthermore, this could lead to healthier cells, especially in relation to neurodegenerative diseases. The company uses advanced methods to find compounds that can help restore proteasome function and is planning to focus on a range of diseases, starting with neurodegenerative ones.

The company plans to use the October 2024 funding to develop proteasome activators to treat complicated illnesses.

## Funding rounds

- Seed, Jul 28, 2021, $15M — Novo Holdings, Apollo Health Ventures

## Investors

- Novo Holdings — Seed
- Apollo Health Ventures (https://capitalatlas.ai/funds/apollo-health-ventures) — Seed